Navigation Links
ImaRx to Report Corporate Updates and 4Q07 Financial Results
Date:3/20/2008

Live Webcast and Conference Call Scheduled for Thursday, March 27TH AT 5 PM

ET

TUCSON, Ariz., March 20 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that the Company will host a live webcast and conference call on Thursday, March 27, 2008, at 5:00 p.m. ET to discuss corporate updates and fourth quarter 2007 financial results.

The live webcast can be accessed through ImaRx's corporate website at http://www.imarx.com and will be archived on the website for 14 days following the event.

Interested parties may access the conference call by dialing (877) 407- 4018 in the U.S. and Canada or (201) 689-8471 internationally. A telephonic replay will be available through April 3, 2008 by dialing (877) 660-6853 in the U.S. and Canada or (201) 612-7415 internationally (Account Number 3055 and Conference ID 279436).

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company commercializing and developing therapies for vascular disorders. The Company's commercialization efforts are currently focused on its FDA approved product, urokinase, for the treatment of acute massive pulmonary embolism. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology.

Cautionary Statement For The Purpose Of The "Safe Harbor" Provisions Of The Private Securities Litigation Reform Act of 1995

Note: Statements made in this press release which are not historical in nature constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
3. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
4. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
5. Vion Reports 2007 Fourth Quarter and Year-End Results
6. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
7. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
8. Warner Chilcott Reports the Death of Its Director James Andress
9. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
10. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
11. Unigene Restates Policy on Analyst Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... GENEVA , July 11, 2014 ... pleased to announce the appointment of John P. ... Campus Biotech   in  Geneva . ... on Campus Biotech in Geneva , ... internationally recognised neuroscientists. John P. Donoghue , founder ...
(Date:7/11/2014)... July 11, 2014 Cayenne Medical, ... specializing in the soft tissue reconstruction segment, announced ... System for surgeries involving the shoulder and extremities. ... a novel, inserter-controlled deployment method. The unique delivery ... deployment, anchor pull-out, or anchor displacement (also commonly ...
(Date:7/10/2014)... July 10, 2014 Deep Knowledge ... Medicine Forum on ‘Commercialising Longevity Research’ and welcomed ... to the London Bioscience Innovation Center for the ... and Aging Analytics Ltd. The meeting highlighted the ... translational research for age-related disease, as well as ...
(Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, and ... purchased a DNA test to unravel the ... a lifetime of memories, sharing, and closeness. In fact, ... genuinely brought the family closer together. , Recently, ... history and prior to taking the genetic ancestry ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... a bioMerieux company that develops innovative oncology diagnostic tests ... from a clinical study evaluating the company,s Breast Cancer ... the study were presented at the 33rd Annual CTRC-AACR ... The company also announced that the Breast Cancer Index ...
... 2010 Pfizer Inc. (NYSE: PFE ) ... it is voluntarily withdrawing Thelin® (sitaxentan) for the treatment ... is approved (the European Union, Canada and Australia).  In ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) Pfizer,s decision ...
... (Dec. 9, 2010) -- Nanotechnologists, marine biologists and signal-processing ... Woods Hole, Mass., and other U.S. universities have won ... Research to unlock the secrets of nature,s best camouflage ... emulate some of the elegant skin colors and patterns ...
Cached Biology Technology:bioTheranostics' Breast Cancer Index(SM) Predicts Risk for Late Recurrence in Early Stage ER-Positive Breast Cancer Patients 2bioTheranostics' Breast Cancer Index(SM) Predicts Risk for Late Recurrence in Early Stage ER-Positive Breast Cancer Patients 3Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety 2Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety 3Nano squid skin: DOD awards $6M for metamaterials research 2Nano squid skin: DOD awards $6M for metamaterials research 3
(Date:7/11/2014)... 2014 Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/11/2014)... type 1 can inhibit voltage-gated calcium channel, ... release. However, some scholars demonstrated that cannabinoid ... influx and increase neurotransmitter release. Dr. Yi ... to Tongji Medical College, Huazhong University of ... voltage-clamp and calcium imaging in cultured trigeminal ...
(Date:7/10/2014)... , June 27, 2014  The American Academy ... Institute of Standards and Technology (NIST) and the ... academic research and forensic science expert members to ... is an element of the NIST,s Organization of ... among the first appointments made to the new ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3
... Ore. -- New research has found that if you want ... or other cruciferous vegetables, you need to eat the real ... absorbed and of far less value if taken as a ... Pauling Institute at Oregon State University, is one of the ...
... has awarded UC Santa Barbara up to $15 million ... shape the future of technology in areas that will ... educate future scientists and engineers and advance the discovery ... novel polymers to next-generation microelectronics. The pioneering institute ...
... them, and although they could be effective in theory, antivirulence ... to be published in the online journal mBio ... to fight infection while avoiding the pitfalls of drug resistance. ... growth of pathogens, but antivirulence drugs prevent disease by ...
Cached Biology News:Health benefits of broccoli require the whole food, not supplements 2Health benefits of broccoli require the whole food, not supplements 3UCSB awarded $15 million by Dow to establish collaborative institute for materials research and education 2UCSB awarded $15 million by Dow to establish collaborative institute for materials research and education 3Can antivirulence drugs stop infections without causing resistance? 2
... Security ChemStation is a ... application for data acquisition, ... searching and reporting, addressing ... data security, integrity, and ...
... for genome-wide microRNA expression profiling and ... Paraflo microfluidic on-chip synthesis platform. These ... our comprehensive microRNA Expression Profiling Service. ... Mammals microRNA Microarray contains all known ...
... Ocean Optics LIBS2000+ Spectrometers (sold separately) in ... Ablation Chamber to offer numerous configuration options ... features include a high-power 1064 nm Nd:YAG ... X-Y sample positioning, laser spot diameter control ...
...
Biology Products: